Black Diamond Therapeutics, Inc. (BDTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 70M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-40M -20M 0 20M 40M 60M Q1 '18: -1.6M Q2 '18: -1.9M Q3 '18: -2.3M Q4 '18: -3M Q1 '19: -3.8M Q2 '19: -7M Q3 '19: -8.1M Q4 '19: -10.3M Q1 '20: -12.9M Q2 '20: -15M Q3 '20: -18.5M Q4 '20: -23.2M Q1 '21: -30.7M Q2 '21: -34.7M Q3 '21: -35.4M Q4 '21: -26.1M Q1 '22: -25.7M Q2 '22: -23.2M Q3 '22: -22.1M Q4 '22: -21.9M Q1 '23: -21.6M Q2 '23: -20M Q3 '23: -24M Q4 '23: -20.9M Q1 '24: -20.2M Q2 '24: -22.1M Q3 '24: -18.1M Q4 '24: -18.3M Q1 '25: 54.5M Q2 '25: -13.4M Q3 '25: -11M Q4 '25: -17.6M Q1 '26: -11.3M Q2 '26: -12.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-40M -20M 0 20M 40M 60M Q1 '18: -1.6M Q2 '18: -1.9M Q3 '18: -2.4M Q4 '18: -3.1M Q1 '19: -3.8M Q2 '19: -12.3M Q3 '19: -9.3M Q4 '19: -9.9M Q1 '20: -12.1M Q2 '20: -14.6M Q3 '20: -17.9M Q4 '20: -22.6M Q1 '21: -30.3M Q2 '21: -34.4M Q3 '21: -35.1M Q4 '21: -25.9M Q1 '22: -25.5M Q2 '22: -22.9M Q3 '22: -21.7M Q4 '22: -21.1M Q1 '23: -20.9M Q2 '23: -19.2M Q3 '23: -23M Q4 '23: -19.4M Q1 '24: -18.2M Q2 '24: -19.9M Q3 '24: -15.6M Q4 '24: -16M Q1 '25: 56.5M Q2 '25: -10.6M Q3 '25: -8.5M Q4 '25: -15.1M Q1 '26: -9M Q2 '26: -9.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q1 '19: -6.9M Q2 '19: -5M Q3 '19: -5.3M Q4 '19: -7.5M Q1 '20: -11.3M Q2 '20: -13.6M Q3 '20: -11.5M Q4 '20: -15.8M Q1 '21: -24.5M Q2 '21: -25.2M Q3 '21: -26.5M Q4 '21: -24M Q1 '22: -28.6M Q2 '22: -18.1M Q3 '22: -16.5M Q4 '22: -21.9M Q1 '23: -20M Q2 '23: -14.4M Q3 '23: -18.4M Q4 '23: -14M Q1 '24: -21.2M Q2 '24: -14.7M Q3 '24: -11.3M Q4 '24: -15.1M Q1 '25: 53.4M Q2 '25: -9.2M Q3 '25: -7.8M Q4 '25: -6.8M Q1 '26: -10.2M Q2 '26: -8M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '19: -6.9M Q2 '19: -5M Q3 '19: -5.3M Q4 '19: -7.5M Q1 '20: -11.3M Q2 '20: -13.6M Q3 '20: -11.5M Q4 '20: -15.9M Q1 '21: -24.5M Q2 '21: -26M Q3 '21: -28M Q4 '21: -24.4M Q1 '22: -28.6M Q2 '22: -18.3M Q3 '22: -16.5M Q4 '22: -21.9M Q1 '23: -20M Q2 '23: -14.4M Q3 '23: -18.4M Q4 '23: -14M Q4 '24: -15.1M Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 23.7M Q2 '20: 35.9M Q3 '20: 35.9M Q1 '21: 36.1M Q2 '21: 36.2M Q3 '21: 36.2M Q1 '22: 36.3M Q2 '22: 36.3M Q3 '22: 36.3M Q1 '23: 36.5M Q2 '23: 36.5M Q3 '23: 50.9M Q1 '24: 51.8M Q2 '24: 55.2M Q3 '24: 56.5M Q1 '25: 57.7M Q2 '25: 56.8M Q3 '25: 56.9M Q1 '26: 57.2M Q2 '26: 57.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '18: -4.42 Q1 '19: -5.49 Q2 '19: -10.53 Q3 '19: -13.87 Q4 '19: -16.99 Q1 '20: -15.63 Q2 '20: -10.05 Q3 '20: -6.05 Q4 '20: -2.05 Q1 '21: -2.38 Q2 '21: -2.92 Q3 '21: -3.39 Q4 '21: -3.47 Q1 '22: -3.33 Q2 '22: -3.01 Q3 '22: -2.64 Q4 '22: -2.52 Q1 '23: -2.39 Q2 '23: -2.28 Q3 '23: -2.13 Q4 '23: -1.88 Q1 '24: -1.66 Q2 '24: -1.50 Q3 '24: -1.33 Q4 '24: -1.27 Q1 '25: 0.06 Q2 '25: 0.23 Q3 '25: 0.36 Q4 '25: 0.39 Q1 '26: -0.75 Q2 '26: -0.73 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.